Not provided
Not provided
Not provided
Not provided
The study terminated on 19-Jan-2011 due to insufficient recruitment of patients. No safety reasons contributed to the termination of the study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The planned study focuses on the effect of a one year Somatropin treatment (0.035 mg/kg/d or 0.067 mg/kg/d) in short children born SGA on neuromuscular function and cognitive performance.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment Group | Active Comparator | Somatropin for 12 months |
|
| Control Group | Other | In the first 6 months no intervention, afterwards Somatropin for 12 months |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Somatropin | Drug | Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months. |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6 | Peak jump power (PJP) was defined as the peak of the calculated power (force multiplied by velocity). It was measured by Leonardo Jumping Platform during two-leg jump. The participant performs 3 jumps and the highest peak (PJP) of the 3 recordings was selected for further calculations. The SDS indicates how similar the participant was to the reference population. | Baseline and Month 6 |
| Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; Two-leg-jump) in Per Protocol (PP) Population at Month 6 | PJP was defined as the peak of the calculated power (force multiplied by velocity). It was measured by Leonardo Jumping Platform during two-leg jump. The participant performs 3 jumps and the highest peak (PJP) of the 3 recordings was selected for further calculations. The SDS indicates how similar the participant was to the reference population. | Baseline and Month 6 |
| Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6 | PJF was defined as the maximum of force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms and as high as possible with the head and chest. It was measured by Leonardo Jumping Platform during two-leg jump. The SDS indicates how similar the participant was to the reference population. | Baseline and Month 6 |
| Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; Two-leg-jump) in Per Protocol (PP) Population at Month 6 | PJF was defined as the maximum of force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms and as high as possible with the head and chest. It was measured by Leonardo Jumping Platform during two-leg jump. The SDS indicates how similar the participant was to the reference population. |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Intellectual Performance of Children Using Kaufmann-Assessment Battery for Children (K-ABC) Test Global Scales at Month 6 | K-ABC was assessed in children between 2.5-12.5 years. Comprised of 16 subtests; 10 mental processing (intelligence) and 6 achievement subtests. Achievement subtests: expressive vocabulary, faces&places, arithmetic, riddles, reading/decoding, reading/comprehension. Sixteen subtests were weighted accordingly to form 5 global scales: sequential processing, simultaneous processing, achievement, non-verbal and mental processing composite. Scores were rated as upper extreme [greater than (>) 131], above average (116-130), average (85-115), below average (70-84), lower extreme [less than (<) 69]. |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Bone Density Using Peripheral Quantitative Computed Tomography (pqCT) at 6 or 12 or 18 Months | Bone Mineral Density (BMD) was measured by pqCT. The Z-score measures the distance of the measured BMD value from the appropriate normal age matched population mean value in units of standard deviation of this population. More negative scores indicate less BMD compared to age matched population and more positive scores indicate higher BMD compared to age matched population. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Berlin | 13353 | Germany | |||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Somatropin | Somatropin 0.035 milligram/kilogram/day (mg/kg/day) was administered subcutaneously (s.c) according to exact body weight specific calculation for 12 months. Dose adjustments were made at 6 month intervals. |
| FG001 | Control Arm | No treatment for initial 6 months in control group, after 6 months, somatropin 0.067 mg/kg/day administered s.c. according to exact body weight specific calculation for 12 months. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Somatropin | Somatropin 0.035 mg/kg/day was administered s.c according to exact body weight specific calculation for 12 months. Dose adjustments were made at 6 month intervals. |
| BG001 | Control Arm |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6 | Peak jump power (PJP) was defined as the peak of the calculated power (force multiplied by velocity). It was measured by Leonardo Jumping Platform during two-leg jump. The participant performs 3 jumps and the highest peak (PJP) of the 3 recordings was selected for further calculations. The SDS indicates how similar the participant was to the reference population. | FAS population included participants who received at least 1 dose of study medication and had at least one post baseline efficacy assessment. Number of participants analyzed (N) signifies participants evaluable for the measure. | Posted | Least Squares Mean | Standard Error | Watt/kilogram (W/kg) | Baseline and Month 6 |
|
Not provided
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Somatropin | Somatropin 0.035 mg/kg/day was administered s.c according to exact body weight specific calculation for 12 months. Dose adjustments were made at 6 month intervals. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cryptorchism | Congenital, familial and genetic disorders | MedDRA v14.0 | Non-systematic Assessment |
The study was prematurely discontinued, therefore not all data was powered.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer, Inc. | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
Not provided
| ID | Term |
|---|---|
| D019382 | Human Growth Hormone |
| ID | Term |
|---|---|
| D013006 | Growth Hormone |
| D010908 | Pituitary Hormones, Anterior |
| D010907 | Pituitary Hormones |
| D036361 | Peptide Hormones |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Somatropin | Drug | Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months. |
|
| Baseline and Month 6 |
| Change From Baseline in Maximum Jump Velocity (Vmax; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6 | Vmax was measured by Leonardo Jumping Platform during two-leg jump. | Baseline and Month 6 |
| Change From Baseline in Maximum Jump Velocity (Vmax; Two-leg-jump) in Per Protocol (PP) Population at Month 6 | Vmax was measured by Leonardo Jumping Platform during two-leg jump. | Baseline and Month 6 |
| Baseline and Month 6 |
| Change From Baseline in Intellectual Performance of Children Using Kaufmann-Assessment Battery for Children (K-ABC) Test Global Scales at Months 12 and 18 | K-ABC was assessed in children between 2.5-12.5 years. Comprised of 16 subtests; 10 mental processing (intelligence) and 6 achievement subtests. Achievement subtests: expressive vocabulary, faces&places, arithmetic, riddles, reading/decoding, reading/comprehension. Sixteen subtests were weighted accordingly to form 5 global scales: sequential processing, simultaneous processing, achievement, non-verbal and mental processing composite. Scores were rated as upper extreme [greater than (>) 131], above average (116-130), average (85-115), below average (70-84), lower extreme [less than (<) 69]. | Baseline, Month 12 and Month 18 |
| Change From Baseline in Intellectual Performance of Children Using Kinderversion Der Testbatterie Zur Aufmerksamkeitsprüfung für Kinder (KITAP) Test at Month 6 | The KITAP is a computer aided standardized neuro-cognitive development test which allows examination of a wide range of attention and executive functions such as shift of attention (Distractibility); simple reaction time (Alertness); "Sustained Attention", change of reaction (Flexibility); "Divided Attention", controlled reaction disposition (Go/No go) and "Vigilance". It has been designed appropriately for children between the age of 6 to 10 years to allow optimal motivation during testing and to increase validity of results. | Baseline and Month 6 |
| Change From Baseline in Intellectual Performance of Children Using Kinderversion Der Testbatterie Zur Aufmerksamkeitsprüfung für Kinder (KITAP) Test at Months 12 and 18 | The KITAP is a computer aided standardized neuro-cognitive development test which allows examination of a wide range of attention and executive functions such as shift of attention (Distractibility); simple reaction time (Alertness); "Sustained Attention", change of reaction (Flexibility); "Divided Attention", controlled reaction disposition (Go/No go) and "Vigilance". It has been designed appropriately for children between the age of 6 to 10 years to allow optimal motivation during testing and to increase validity of results. | Baseline, Month 12 and Month 18 |
| Change From Baseline in Intellectual Performance of Children Using Non-verbal Learning Test (NVLT) at Month 6 | NVLT was assessed for visual memorization that was difficult to verbalize. Test recorded instability index, T-scores[sum of differences of correct {C} - incorrect {IC} "Yes" answers(1);sum of C "Yes" answers(2);sum of IC "Yes" answers(3);sum of differences of C-IC "Yes" answers with high associative items{ 87%-95%}(4);sum of differences of C-IC "Yes" answers with low associative items{ 54%-64%}(5); difference between difference values for high and low associative items(6)].Scores were rated as below average(<40), average(40-60), above average(>60) and working time ranging between 9-12 minutes. | Baseline and Month 6 |
| Change From Baseline in Intellectual Performance of Children Using Non-verbal Learning Test (NVLT) at Months 12 and 18 | NVLT was assessed for visual memorization that was difficult to verbalize. Test recorded instability index, T-scores[sum of differences of correct {C} - incorrect {IC} "Yes" answers(1);sum of C "Yes" answers(2);sum of IC "Yes" answers(3);sum of differences of C-IC "Yes" answers with high associative items{ 87%-95%}(4);sum of differences of C-IC "Yes" answers with low associative items{ 54%-64%}(5); difference between difference values for high and low associative items(6)].Scores were rated as below average(<40), average(40-60), above average(>60) and working time ranging between 9-12 minutes. | Baseline, Month 12 and Month 18 |
| Change From Baseline in Intellectual Performance of Children Using Child Behavior Checklist 4-18 Years (CBCL 4-18) at Months 6, 12 and 18 | CBCL was standardized for children ages 4 to 18 years and measured child internalizing and externalizing behaviors and total problems. The 4-18 years' checklist contains 140 questions and responses were recorded on a Likert scale: 0 = Not True, 1 = Somewhat or Sometimes True, 2 = Very True or Often True. The range of possible values was 0-280 (0=good to 280=worst). | Baseline, Month 6, Month 12 and Month 18 |
| Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; One-leg-jump) at Months 6, 12 and 18 | PJP was defined as the peak of the calculated power (force multiplied by velocity). It was measured by Leonardo Jumping Platform during one leg jump. The participant performs 3 jumps and the highest peak (PJP) of the 3 recordings was selected for further calculations. The SDS indicates how similar the participant was to the reference population. | Baseline, Month 6 , Month 12 and Month 18 |
| Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; One-leg-jump) at Months 6, 12 and 18 | PJF was defined as the maximum of force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms and as high as possible with the head and chest. It was measured by Leonardo Jumping Platform during one leg jump. The SDS indicates how similar the participant was to the reference population. | Baseline, Month 6, Month 12 and Month 18 |
| Change From Baseline in Maximum Jump Velocity (Vmax; One-leg-jump) at Months 6, 12 and 18 | Vmax was measured by Leonardo Jumping Platform during one leg jump. | Baseline, Month 6, Month 12 and Month 18 |
| Change From Baseline in Five-chair Rising Test- Peak Jump Power (PJP) at Month 6 | The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJP is defined as the peak of the calculated power (force multiplied by velocity). | Baseline and Month 6 |
| Change From Baseline in Five-chair Rising Test-Peak Jump Power (PJP) at Months 12 and 18 | The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJP is defined as the peak of the calculated power (force multiplied by velocity). | Baseline, Month 12 and Month 18 |
| Change From Baseline in Five-chair Rising Test-Peak Jump Force (PJF) at Month 6 | The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJF is the maximum force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms as high as possible with the head and chest. | Baseline and Month 6 |
| Change From Baseline in Five-chair Rising Test-Peak Jump Force (PJF) at Months 12 and 18 | The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJF is the maximum force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms as high as possible with the head and chest. | Baseline, Month 12 and Month 18 |
| Change From Baseline in Five-chair Rising Test-Maximum Jump Velocity (Vmax) at Month 6 | The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). Vmax is defined as the maximum jump velocity. | Baseline and Month 6 |
| Change From Baseline in Five-chair Rising Test-Maximum Jump Velocity (Vmax) at Months 12 and 18 | The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). Vmax is defined as the maximum jump velocity. | Baseline, Month 12 and Month 18 |
| Change From Baseline in Five-chair Rising Test (Time to Perform the Tasks) at Month 6 | Chair rising test is performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: 5 repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over chest (time to perform tasks, maximal PJP, maximal velocity and maximal PJF). Time to perform task includes: Average (avg) rise time which is avg time to perform 1 rise, avg time per test is the avg time to perform 1 test (rise and sitting down) and total time to perform 5 tests. | Baseline and Month 6 |
| Change From Baseline in Five-chair Rising Test (Time to Perform the Tasks) at Months 12 and 18 | Chair rising test is performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: 5 repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over chest (time to perform tasks, maximal PJP, maximal velocity and maximal PJF). Time to perform task includes: Average (avg) rise time which is avg time to perform 1 rise, avg time per test is the avg time to perform 1 test (rise and sitting down) and total time to perform 5 tests. | Baseline, Month 12 and Month 18 |
| Change From Baseline in One-chair Rising Test-Peak Jump Power (PJP) at Months 6, 12 and 18 | The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement to stand up. Test allows diagnostics of movement deficits using Leonardo jump plate. One stand up test: rising from a chair on the jump plate as quickly as possible with arms crossed over the chest (analysis of time, PJP, PJF and time of fastest rising). PJP is defined as the peak of the calculated power (force multiplied by velocity). | Baseline, Month 6 , Month 12 and Month 18 |
| Change From Baseline in One-chair Rising Test-Peak Jump Force (PJF) at Months 6, 12 and 18 | The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement to stand up. Test allows diagnostics of movement deficits using Leonardo jump plate. One stand up test: rising from a chair on the jump plate as quickly as possible with arms crossed over the chest (analysis of time, PJP, PJF and time of fastest rising). PJF is the maximum force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms as high as possible with the head and chest. | Baseline, Month 6 , Month 12 and Month 18 |
| Change From Baseline in One-chair Rising Test (Time to Perform the Tasks) at Months 6, 12 and 18 | The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement to stand up. Test allows diagnostics of movement deficits using Leonardo jump plate. One stand up test: rising from a chair on the jump plate as quickly as possible with arms crossed over the chest (analysis of time, PJP, PJF and time of fastest rising). | Baseline, Month 6 , Month 12 and Month 18 |
| Change From Baseline in Maximal Isometric Grip Force-Standard Deviation Score (MIGF-SDS) at Month 6 | MIGF was assessed using standard adjustable Jamar dynamometer. MIGF (in Newtons) was calculated by multiplying the dynamometer reading (in kilograms) by a factor of 9.81. The SDS indicates how similar the participant was to the reference population. | Baseline and Month 6 |
| Change From Baseline in Maximal Isometric Grip Force-Standard Deviation Score (MIGF-SDS) at Months 12 and 18 | MIGF was assessed using standard adjustable Jamar dynamometer. MIGF (in Newtons) was calculated by multiplying the dynamometer reading (in kilograms) by a factor of 9.81. The SDS indicates how similar the participant was to the reference population. | Baseline, Month 12 and Month 18 |
| Mean Upper Arm Circumference | Baseline, Month 6, Month 12 and Month 18 |
| Mean Thigh Circumference | Thigh measurements were taken as a mean of 3 consecutive measurements at upper thigh about an inch down from the crotch line. | Baseline, Month 6, Month 12 and Month 18 |
| Mean Calf Circumference | Calf measurements were taken as a mean of 3 consecutive measurements at largest part of calf muscle, usually about 4 inches down from below the knee. | Baseline, Month 6, Month 12 and Month 18 |
| Mean Height at Month 6 | Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. | Month 6 |
| Mean Height at Months 12 and 18 | Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. | Month 12 and Month 18 |
| Mean Growth Velocity at Month 6 | Growth velocity measures the annual rate of increase in height. | Month 6 |
| Mean Growth Velocity at Months 12 and 18 | Growth velocity measures the annual rate of increase in height. | Month 12 and Month 18 |
| Mean Height-Standard Deviation Score (SDS) at Month 6 | Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population. | Month 6 |
| Mean Height-Standard Deviation Score (SDS) at Months 12 and 18 | Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population. | Month 12 and Month 18 |
| Mean Growth Velocity-Standard Deviation Score (SDS) at Month 6 | Growth velocity measures the annual rate of increase in height. The SDS indicates how similar the participant is to the reference population. | Month 6 |
| Mean Growth Velocity-Standard Deviation Score (SDS) at Months 12 and 18 | Month 12 and Month 18 |
| Change From Baseline in Height-Standard Deviation Score (SDS) at Month 6 | Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population. | Baseline and Month 6 |
| Change From Baseline in Height-Standard Deviation Score (SDS) at Months 12 and 18 | Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population. | Baseline, Month 12 and Month 18 |
| Change From Baseline in Growth Velocity-Standard Deviation Score (SDS) at Month 6 | Growth velocity measures the annual rate of increase in height. The SDS indicates how similar the participant is to the reference population. | Baseline and Month 6 |
| Change From Baseline in Growth Velocity-Standard Deviation Score (SDS) at Months 12 and 18 | Growth velocity measures the annual rate of increase in height. The SDS indicates how similar the participant is to the reference population. | Baseline, Month 12 and Month 18 |
| Sitting Height-Standard Deviation Score (SDS) | Sitting height was measured using a stadiometer with a specialized chair. The SDS indicates how similar the participant was to the reference population. | Baseline, Month 6, Month 12 and Month 18 |
| Body Mass Index-Standard Deviation Score (BMI-SDS) | The BMI was used to measure body fat based on height and weight. It was calculated by body weight (kg) divided by the height (m) squared. The SDS indicates how similar the participant was to the reference population. | Baseline, Month 6, Month 12 and Month 18 |
| Change From Baseline in Head Circumference at Months 6, 12 and 18 | The maximum head circumference (usually horizontal just above the eyebrow ridges), was measured from just above the glabella area to the area near the top of the occipital bone (opisthocranion). | Baseline, Month 6, Month 12 and Month 18 |
| Change From Baseline in Head Circumference-Standard Deviation Score (SDS) at Months 6, 12 and 18 | The maximum head circumference (usually horizontal just above the eyebrow ridges), was measured from just above the glabella area to the area near the top of the occipital bone (opisthocranion). The SDS indicates how similar the participant was to the reference population. | Baseline, Month 6, Month 12 and Month 18 |
| Change From Baseline in Skinfold Thickness-Standard Deviation Score (SDS) at Month 6 | Triceps, supra-iliac and subscapular skinfolds were measured on the right side of the body to the nearest 0.1 mm with a Holtain skinfold caliper. The measurement was performed at the left side of the participant. Triceps skinfold thickness was measured halfway down the left upper arm, while the arm was hanging relaxed at the participant's side. Suprascapular skinfold was measured laterally just below the angle of the left scapula. Suprailiac skinfold was measured just above the iliac crest in the middle-axillary line. SDS indicates how similar the participant was to the reference population. | Baseline and Month 6 |
| Change From Baseline in Skinfold Thickness-Standard Deviation Score (SDS) at Months 12 and 18 | Triceps, supra-iliac and subscapular skinfolds were measured on the right side of the body to the nearest 0.1 mm with a Holtain skinfold caliper. The measurement was performed at the left side of the participant. Triceps skinfold thickness was measured halfway down the left upper arm, while the arm was hanging relaxed at the participant's side. Suprascapular skinfold was measured laterally just below the angle of the left scapula. Suprailiac skinfold was measured just above the iliac crest in the middle-axillary line. SDS indicates how similar the participant was to the reference population. | Baseline, Month 12 and Month 18 |
| Baseline, Month 6, Month 12 and Month 18 |
| Change From Baseline in Bone Structure Using Peripheral Quantitative Computed Tomography (pqCT) at 6 or 12 or 18 Months | Bone structure was measured by pqCT.Parameters included:total area,cortical area,marrow area,cortical thickness,cortical density of the radius,bone strength,cross-sectional muscle and fat area,total bone density,bone mineral count,trabecular BMD,bone cross-sectional area.Baseline and post-baseline SDS values transformed to age and sex specific z-score([Ln(test result/M)]/S);Ln=natural logarithm;M=age-/height- and sex-specific mean value;S=age-/height- and sex-specific coefficient of variation).Positive values are above the average for participant's age and sex;negative values are below. | Baseline, Month 6, Month 12 and Month 18 |
| Change From Baseline in Bone Stability Using Peripheral Quantitative Computed Tomography (pqCT) at 6 or 12 or 18 Months | Bone stability was measured by pqCT. Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)]/S); Ln=natural logarithm; M=age- (or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average. | Baseline, Month 6, Month 12 and Month 18 |
| Bonn |
| 53113 |
| Germany |
| Pfizer Investigational Site | Cologne | 50937 | Germany |
| Pfizer Investigational Site | Datteln | 45711 | Germany |
| Pfizer Investigational Site | Dresden | 01307 | Germany |
| Pfizer Investigational Site | Erlangen | 91054 | Germany |
| Pfizer Investigational Site | Essen | 45122 | Germany |
| Pfizer Investigational Site | Heidelberg | 69120 | Germany |
| Pfizer Investigational Site | Kiel | 24105 | Germany |
| Pfizer Investigational Site | München | 80337 | Germany |
| Terminated by sponsor |
|
| Randomized but not treated |
|
No treatment for initial 6 months in control group, after 6 months, somatropin 0.067 mg/kg/day administered s.c. according to exact body weight specific calculation for 12 months.
| BG002 | Total | Total of all reporting groups |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| OG001 | Control Arm | No treatment for initial 6 months in control group, after 6 months, somatropin 0.067 mg/kg/day administered s.c. according to exact body weight specific calculation for 12 months. |
|
|
|
| Primary | Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; Two-leg-jump) in Per Protocol (PP) Population at Month 6 | PJP was defined as the peak of the calculated power (force multiplied by velocity). It was measured by Leonardo Jumping Platform during two-leg jump. The participant performs 3 jumps and the highest peak (PJP) of the 3 recordings was selected for further calculations. The SDS indicates how similar the participant was to the reference population. | PP population included participants who received the study medication for at least 22 weeks. Number of participants analyzed (N) signifies participants evaluable for the measure. | Posted | Least Squares Mean | Standard Error | W/kg | Baseline and Month 6 |
|
|
|
|
| Primary | Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6 | PJF was defined as the maximum of force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms and as high as possible with the head and chest. It was measured by Leonardo Jumping Platform during two-leg jump. The SDS indicates how similar the participant was to the reference population. | FAS population included participants who received at least 1 dose of study medication and had at least one post baseline efficacy assessment. Number of participants analyzed (N) signifies participants evaluable for the measure. | Posted | Least Squares Mean | Standard Error | Newtons | Baseline and Month 6 |
|
|
|
| Secondary | Change From Baseline in Intellectual Performance of Children Using Kaufmann-Assessment Battery for Children (K-ABC) Test Global Scales at Month 6 | K-ABC was assessed in children between 2.5-12.5 years. Comprised of 16 subtests; 10 mental processing (intelligence) and 6 achievement subtests. Achievement subtests: expressive vocabulary, faces&places, arithmetic, riddles, reading/decoding, reading/comprehension. Sixteen subtests were weighted accordingly to form 5 global scales: sequential processing, simultaneous processing, achievement, non-verbal and mental processing composite. Scores were rated as upper extreme [greater than (>) 131], above average (116-130), average (85-115), below average (70-84), lower extreme [less than (<) 69]. | FAS population included participants who received at least 1 dose of study medication and had at least one post baseline efficacy assessment. | Posted | Mean | Standard Deviation | Units on a scale | Baseline and Month 6 |
|
|
|
|
| Secondary | Change From Baseline in Intellectual Performance of Children Using Kaufmann-Assessment Battery for Children (K-ABC) Test Global Scales at Months 12 and 18 | K-ABC was assessed in children between 2.5-12.5 years. Comprised of 16 subtests; 10 mental processing (intelligence) and 6 achievement subtests. Achievement subtests: expressive vocabulary, faces&places, arithmetic, riddles, reading/decoding, reading/comprehension. Sixteen subtests were weighted accordingly to form 5 global scales: sequential processing, simultaneous processing, achievement, non-verbal and mental processing composite. Scores were rated as upper extreme [greater than (>) 131], above average (116-130), average (85-115), below average (70-84), lower extreme [less than (<) 69]. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | Units on a scale | Baseline, Month 12 and Month 18 |
|
|
| Secondary | Change From Baseline in Intellectual Performance of Children Using Kinderversion Der Testbatterie Zur Aufmerksamkeitsprüfung für Kinder (KITAP) Test at Month 6 | The KITAP is a computer aided standardized neuro-cognitive development test which allows examination of a wide range of attention and executive functions such as shift of attention (Distractibility); simple reaction time (Alertness); "Sustained Attention", change of reaction (Flexibility); "Divided Attention", controlled reaction disposition (Go/No go) and "Vigilance". It has been designed appropriately for children between the age of 6 to 10 years to allow optimal motivation during testing and to increase validity of results. | FAS population included participants who received at least 1 dose of study medication and had at least one post baseline efficacy assessment. Number of participants analyzed (N) signifies participants evaluable for the measure and 'n' signifies participants who received the study drug and evaluated at the time point for each group respectively. | Posted | Mean | Standard Deviation | Seconds | Baseline and Month 6 |
|
|
|
|
| Secondary | Change From Baseline in Intellectual Performance of Children Using Kinderversion Der Testbatterie Zur Aufmerksamkeitsprüfung für Kinder (KITAP) Test at Months 12 and 18 | The KITAP is a computer aided standardized neuro-cognitive development test which allows examination of a wide range of attention and executive functions such as shift of attention (Distractibility); simple reaction time (Alertness); "Sustained Attention", change of reaction (Flexibility); "Divided Attention", controlled reaction disposition (Go/No go) and "Vigilance". It has been designed appropriately for children between the age of 6 to 10 years to allow optimal motivation during testing and to increase validity of results. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | Seconds | Baseline, Month 12 and Month 18 |
|
|
| Secondary | Change From Baseline in Intellectual Performance of Children Using Non-verbal Learning Test (NVLT) at Month 6 | NVLT was assessed for visual memorization that was difficult to verbalize. Test recorded instability index, T-scores[sum of differences of correct {C} - incorrect {IC} "Yes" answers(1);sum of C "Yes" answers(2);sum of IC "Yes" answers(3);sum of differences of C-IC "Yes" answers with high associative items{ 87%-95%}(4);sum of differences of C-IC "Yes" answers with low associative items{ 54%-64%}(5); difference between difference values for high and low associative items(6)].Scores were rated as below average(<40), average(40-60), above average(>60) and working time ranging between 9-12 minutes. | FAS population included participants who received at least 1 dose of study medication and had at least one post baseline efficacy assessment. Number of participants analyzed (N) signifies participants evaluable for the measure. | Posted | Mean | Standard Deviation | Units on a scale | Baseline and Month 6 |
|
|
|
| Secondary | Change From Baseline in Intellectual Performance of Children Using Non-verbal Learning Test (NVLT) at Months 12 and 18 | NVLT was assessed for visual memorization that was difficult to verbalize. Test recorded instability index, T-scores[sum of differences of correct {C} - incorrect {IC} "Yes" answers(1);sum of C "Yes" answers(2);sum of IC "Yes" answers(3);sum of differences of C-IC "Yes" answers with high associative items{ 87%-95%}(4);sum of differences of C-IC "Yes" answers with low associative items{ 54%-64%}(5); difference between difference values for high and low associative items(6)].Scores were rated as below average(<40), average(40-60), above average(>60) and working time ranging between 9-12 minutes. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | Units on a scale | Baseline, Month 12 and Month 18 |
|
|
| Secondary | Change From Baseline in Intellectual Performance of Children Using Child Behavior Checklist 4-18 Years (CBCL 4-18) at Months 6, 12 and 18 | CBCL was standardized for children ages 4 to 18 years and measured child internalizing and externalizing behaviors and total problems. The 4-18 years' checklist contains 140 questions and responses were recorded on a Likert scale: 0 = Not True, 1 = Somewhat or Sometimes True, 2 = Very True or Often True. The range of possible values was 0-280 (0=good to 280=worst). | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | Units on a scale | Baseline, Month 6, Month 12 and Month 18 |
|
|
| Secondary | Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; One-leg-jump) at Months 6, 12 and 18 | PJP was defined as the peak of the calculated power (force multiplied by velocity). It was measured by Leonardo Jumping Platform during one leg jump. The participant performs 3 jumps and the highest peak (PJP) of the 3 recordings was selected for further calculations. The SDS indicates how similar the participant was to the reference population. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | W/kg | Baseline, Month 6 , Month 12 and Month 18 |
|
|
| Secondary | Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; One-leg-jump) at Months 6, 12 and 18 | PJF was defined as the maximum of force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms and as high as possible with the head and chest. It was measured by Leonardo Jumping Platform during one leg jump. The SDS indicates how similar the participant was to the reference population. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | Newtons | Baseline, Month 6, Month 12 and Month 18 |
|
|
| Secondary | Change From Baseline in Maximum Jump Velocity (Vmax; One-leg-jump) at Months 6, 12 and 18 | Vmax was measured by Leonardo Jumping Platform during one leg jump. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | m/s | Baseline, Month 6, Month 12 and Month 18 |
|
|
| Secondary | Change From Baseline in Five-chair Rising Test- Peak Jump Power (PJP) at Month 6 | The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJP is defined as the peak of the calculated power (force multiplied by velocity). | FAS population included participants who received at least 1 dose of study medication and had at least one post baseline efficacy assessment. Number of participants analyzed (N) signifies participants evaluable for the measure. | Posted | Mean | Standard Deviation | kilowatt (kW) | Baseline and Month 6 |
|
|
|
| Secondary | Change From Baseline in Five-chair Rising Test-Peak Jump Power (PJP) at Months 12 and 18 | The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJP is defined as the peak of the calculated power (force multiplied by velocity). | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | kW | Baseline, Month 12 and Month 18 |
|
|
| Secondary | Change From Baseline in Five-chair Rising Test-Peak Jump Force (PJF) at Month 6 | The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJF is the maximum force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms as high as possible with the head and chest. | FAS population included participants who received at least 1 dose of study medication and had at least one post baseline efficacy assessment. Number of participants analyzed (N) signifies participants evaluable for the measure. | Posted | Mean | Standard Deviation | kilonewton (kN) | Baseline and Month 6 |
|
|
|
| Secondary | Change From Baseline in Five-chair Rising Test-Peak Jump Force (PJF) at Months 12 and 18 | The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJF is the maximum force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms as high as possible with the head and chest. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | kN | Baseline, Month 12 and Month 18 |
|
|
| Secondary | Change From Baseline in Five-chair Rising Test-Maximum Jump Velocity (Vmax) at Month 6 | The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). Vmax is defined as the maximum jump velocity. | FAS population included participants who received at least 1 dose of study medication and had at least one post baseline efficacy assessment. Number of participants analyzed (N) signifies participants evaluable for the measure. | Posted | Mean | Standard Deviation | m/s | Baseline and Month 6 |
|
|
|
| Secondary | Change From Baseline in Five-chair Rising Test-Maximum Jump Velocity (Vmax) at Months 12 and 18 | The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). Vmax is defined as the maximum jump velocity. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | m/s | Baseline, Month 12 and Month 18 |
|
|
| Secondary | Change From Baseline in Five-chair Rising Test (Time to Perform the Tasks) at Month 6 | Chair rising test is performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: 5 repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over chest (time to perform tasks, maximal PJP, maximal velocity and maximal PJF). Time to perform task includes: Average (avg) rise time which is avg time to perform 1 rise, avg time per test is the avg time to perform 1 test (rise and sitting down) and total time to perform 5 tests. | FAS population included participants who received at least 1 dose of study medication and had at least one post baseline efficacy assessment. Number of participants analyzed (N) signifies participants evaluable for the measure. | Posted | Mean | Standard Deviation | seconds | Baseline and Month 6 |
|
|
|
| Secondary | Change From Baseline in Five-chair Rising Test (Time to Perform the Tasks) at Months 12 and 18 | Chair rising test is performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: 5 repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over chest (time to perform tasks, maximal PJP, maximal velocity and maximal PJF). Time to perform task includes: Average (avg) rise time which is avg time to perform 1 rise, avg time per test is the avg time to perform 1 test (rise and sitting down) and total time to perform 5 tests. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | seconds | Baseline, Month 12 and Month 18 |
|
|
| Secondary | Change From Baseline in One-chair Rising Test-Peak Jump Power (PJP) at Months 6, 12 and 18 | The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement to stand up. Test allows diagnostics of movement deficits using Leonardo jump plate. One stand up test: rising from a chair on the jump plate as quickly as possible with arms crossed over the chest (analysis of time, PJP, PJF and time of fastest rising). PJP is defined as the peak of the calculated power (force multiplied by velocity). | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | kW | Baseline, Month 6 , Month 12 and Month 18 |
|
|
| Secondary | Change From Baseline in One-chair Rising Test-Peak Jump Force (PJF) at Months 6, 12 and 18 | The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement to stand up. Test allows diagnostics of movement deficits using Leonardo jump plate. One stand up test: rising from a chair on the jump plate as quickly as possible with arms crossed over the chest (analysis of time, PJP, PJF and time of fastest rising). PJF is the maximum force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms as high as possible with the head and chest. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | kN | Baseline, Month 6 , Month 12 and Month 18 |
|
|
| Secondary | Change From Baseline in One-chair Rising Test (Time to Perform the Tasks) at Months 6, 12 and 18 | The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement to stand up. Test allows diagnostics of movement deficits using Leonardo jump plate. One stand up test: rising from a chair on the jump plate as quickly as possible with arms crossed over the chest (analysis of time, PJP, PJF and time of fastest rising). | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | seconds | Baseline, Month 6 , Month 12 and Month 18 |
|
|
| Secondary | Change From Baseline in Maximal Isometric Grip Force-Standard Deviation Score (MIGF-SDS) at Month 6 | MIGF was assessed using standard adjustable Jamar dynamometer. MIGF (in Newtons) was calculated by multiplying the dynamometer reading (in kilograms) by a factor of 9.81. The SDS indicates how similar the participant was to the reference population. | FAS population included participants who received at least 1 dose of study medication and had at least one post baseline efficacy assessment. Number of participants analyzed (N) signifies participants evaluable for the measure. | Posted | Least Squares Mean | Standard Error | kg | Baseline and Month 6 |
|
|
|
|
| Secondary | Change From Baseline in Maximal Isometric Grip Force-Standard Deviation Score (MIGF-SDS) at Months 12 and 18 | MIGF was assessed using standard adjustable Jamar dynamometer. MIGF (in Newtons) was calculated by multiplying the dynamometer reading (in kilograms) by a factor of 9.81. The SDS indicates how similar the participant was to the reference population. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Least Squares Mean | Standard Error | kg | Baseline, Month 12 and Month 18 |
|
|
| Other Pre-specified | Change From Baseline in Bone Density Using Peripheral Quantitative Computed Tomography (pqCT) at 6 or 12 or 18 Months | Bone Mineral Density (BMD) was measured by pqCT. The Z-score measures the distance of the measured BMD value from the appropriate normal age matched population mean value in units of standard deviation of this population. More negative scores indicate less BMD compared to age matched population and more positive scores indicate higher BMD compared to age matched population. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Least Squares Mean | Standard Error | z-score | Baseline, Month 6, Month 12 and Month 18 |
|
|
| Other Pre-specified | Change From Baseline in Bone Structure Using Peripheral Quantitative Computed Tomography (pqCT) at 6 or 12 or 18 Months | Bone structure was measured by pqCT.Parameters included:total area,cortical area,marrow area,cortical thickness,cortical density of the radius,bone strength,cross-sectional muscle and fat area,total bone density,bone mineral count,trabecular BMD,bone cross-sectional area.Baseline and post-baseline SDS values transformed to age and sex specific z-score([Ln(test result/M)]/S);Ln=natural logarithm;M=age-/height- and sex-specific mean value;S=age-/height- and sex-specific coefficient of variation).Positive values are above the average for participant's age and sex;negative values are below. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Least Squares Mean | Standard Error | z-score | Baseline, Month 6, Month 12 and Month 18 |
|
|
| Other Pre-specified | Change From Baseline in Bone Stability Using Peripheral Quantitative Computed Tomography (pqCT) at 6 or 12 or 18 Months | Bone stability was measured by pqCT. Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)]/S); Ln=natural logarithm; M=age- (or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Least Squares Mean | Standard Error | z-score | Baseline, Month 6, Month 12 and Month 18 |
|
|
| Secondary | Mean Upper Arm Circumference | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | centimeter (cm) | Baseline, Month 6, Month 12 and Month 18 |
|
|
| Secondary | Mean Thigh Circumference | Thigh measurements were taken as a mean of 3 consecutive measurements at upper thigh about an inch down from the crotch line. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | cm | Baseline, Month 6, Month 12 and Month 18 |
|
|
| Secondary | Mean Calf Circumference | Calf measurements were taken as a mean of 3 consecutive measurements at largest part of calf muscle, usually about 4 inches down from below the knee. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | cm | Baseline, Month 6, Month 12 and Month 18 |
|
|
| Secondary | Mean Height at Month 6 | Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. | FAS population included participants who received at least 1 dose of study medication and had at least one post baseline efficacy assessment. | Posted | Mean | Standard Deviation | cm | Month 6 |
|
|
|
| Secondary | Mean Height at Months 12 and 18 | Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | cm | Month 12 and Month 18 |
|
|
| Secondary | Mean Growth Velocity at Month 6 | Growth velocity measures the annual rate of increase in height. | FAS population included participants who received at least 1 dose of study medication and had at least one post baseline efficacy assessment. | Posted | Mean | Standard Deviation | cm/year | Month 6 |
|
|
|
| Secondary | Mean Growth Velocity at Months 12 and 18 | Growth velocity measures the annual rate of increase in height. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | cm/year | Month 12 and Month 18 |
|
|
| Secondary | Mean Height-Standard Deviation Score (SDS) at Month 6 | Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population. | FAS population included participants who received at least 1 dose of study medication and had at least one post baseline efficacy assessment. | Posted | Mean | Standard Deviation | cm | Month 6 |
|
|
|
| Secondary | Mean Height-Standard Deviation Score (SDS) at Months 12 and 18 | Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | cm | Month 12 and Month 18 |
|
|
| Secondary | Mean Growth Velocity-Standard Deviation Score (SDS) at Month 6 | Growth velocity measures the annual rate of increase in height. The SDS indicates how similar the participant is to the reference population. | FAS population included participants who received at least 1 dose of study medication and had at least one post baseline efficacy assessment. | Posted | Mean | Standard Deviation | cm/year | Month 6 |
|
|
|
| Secondary | Mean Growth Velocity-Standard Deviation Score (SDS) at Months 12 and 18 | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | cm/year | Month 12 and Month 18 |
|
|
| Secondary | Change From Baseline in Height-Standard Deviation Score (SDS) at Month 6 | Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population. | FAS population included participants who received at least 1 dose of study medication and had at least one post baseline efficacy assessment. | Posted | Least Squares Mean | Standard Error | cm | Baseline and Month 6 |
|
|
|
|
| Secondary | Change From Baseline in Height-Standard Deviation Score (SDS) at Months 12 and 18 | Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Least Squares Mean | Standard Error | cm | Baseline, Month 12 and Month 18 |
|
|
| Secondary | Change From Baseline in Growth Velocity-Standard Deviation Score (SDS) at Month 6 | Growth velocity measures the annual rate of increase in height. The SDS indicates how similar the participant is to the reference population. | FAS population included participants who received at least 1 dose of study medication and had at least one post baseline efficacy assessment. Number of participants analyzed (N) signifies participants evaluable for the measure. | Posted | Least Squares Mean | Standard Error | cm/year | Baseline and Month 6 |
|
|
|
|
| Secondary | Change From Baseline in Growth Velocity-Standard Deviation Score (SDS) at Months 12 and 18 | Growth velocity measures the annual rate of increase in height. The SDS indicates how similar the participant is to the reference population. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Least Squares Mean | Standard Error | cm/year | Baseline, Month 12 and Month 18 |
|
|
| Primary | Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; Two-leg-jump) in Per Protocol (PP) Population at Month 6 | PJF was defined as the maximum of force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms and as high as possible with the head and chest. It was measured by Leonardo Jumping Platform during two-leg jump. The SDS indicates how similar the participant was to the reference population. | PP population included participants who received the study medication for at least 22 weeks. Number of participants analyzed (N) signifies participants evaluable for the measure. | Posted | Least Squares Mean | Standard Error | Newtons | Baseline and Month 6 |
|
|
|
| Primary | Change From Baseline in Maximum Jump Velocity (Vmax; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6 | Vmax was measured by Leonardo Jumping Platform during two-leg jump. | FAS population included participants who received at least 1 dose of study medication and had at least one post baseline efficacy assessment. Number of participants analyzed (N) signifies participants evaluable for the measure. | Posted | Least Squares Mean | Standard Error | Meter/second (m/s) | Baseline and Month 6 |
|
|
|
| Primary | Change From Baseline in Maximum Jump Velocity (Vmax; Two-leg-jump) in Per Protocol (PP) Population at Month 6 | Vmax was measured by Leonardo Jumping Platform during two-leg jump. | PP population included participants who received the study medication for at least 22 weeks. Number of participants analyzed (N) signifies participants evaluable for the measure. | Posted | Least Squares Mean | Standard Error | m/s | Baseline and Month 6 |
|
|
|
| Secondary | Sitting Height-Standard Deviation Score (SDS) | Sitting height was measured using a stadiometer with a specialized chair. The SDS indicates how similar the participant was to the reference population. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | cm | Baseline, Month 6, Month 12 and Month 18 |
|
|
| Secondary | Body Mass Index-Standard Deviation Score (BMI-SDS) | The BMI was used to measure body fat based on height and weight. It was calculated by body weight (kg) divided by the height (m) squared. The SDS indicates how similar the participant was to the reference population. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | Kilogram per square meter (kg/m^2) | Baseline, Month 6, Month 12 and Month 18 |
|
|
| Secondary | Change From Baseline in Head Circumference at Months 6, 12 and 18 | The maximum head circumference (usually horizontal just above the eyebrow ridges), was measured from just above the glabella area to the area near the top of the occipital bone (opisthocranion). | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | cm | Baseline, Month 6, Month 12 and Month 18 |
|
|
| Secondary | Change From Baseline in Head Circumference-Standard Deviation Score (SDS) at Months 6, 12 and 18 | The maximum head circumference (usually horizontal just above the eyebrow ridges), was measured from just above the glabella area to the area near the top of the occipital bone (opisthocranion). The SDS indicates how similar the participant was to the reference population. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Mean | Standard Deviation | cm | Baseline, Month 6, Month 12 and Month 18 |
|
|
| Secondary | Change From Baseline in Skinfold Thickness-Standard Deviation Score (SDS) at Month 6 | Triceps, supra-iliac and subscapular skinfolds were measured on the right side of the body to the nearest 0.1 mm with a Holtain skinfold caliper. The measurement was performed at the left side of the participant. Triceps skinfold thickness was measured halfway down the left upper arm, while the arm was hanging relaxed at the participant's side. Suprascapular skinfold was measured laterally just below the angle of the left scapula. Suprailiac skinfold was measured just above the iliac crest in the middle-axillary line. SDS indicates how similar the participant was to the reference population. | FAS population included participants who received at least 1 dose of study medication and had at least one post baseline efficacy assessment. | Posted | Least Squares Mean | Standard Error | Millimeter (mm) | Baseline and Month 6 |
|
|
|
|
| Secondary | Change From Baseline in Skinfold Thickness-Standard Deviation Score (SDS) at Months 12 and 18 | Triceps, supra-iliac and subscapular skinfolds were measured on the right side of the body to the nearest 0.1 mm with a Holtain skinfold caliper. The measurement was performed at the left side of the participant. Triceps skinfold thickness was measured halfway down the left upper arm, while the arm was hanging relaxed at the participant's side. Suprascapular skinfold was measured laterally just below the angle of the left scapula. Suprailiac skinfold was measured just above the iliac crest in the middle-axillary line. SDS indicates how similar the participant was to the reference population. | Data were not analyzed as study was prematurely terminated due to insufficient number of participants. | Posted | Least Squares Mean | Standard Error | mm | Baseline, Month 12 and Month 18 |
|
|
| 0 |
| 12 |
| 10 |
| 12 |
| EG001 | Control Arm | No treatment for initial 6 months in control group, after 6 months, somatropin 0.067 mg/kg/day administered s.c. according to exact body weight specific calculation for 12 months. | 0 | 11 | 7 | 11 |
| Hypothyroidism | Endocrine disorders | MedDRA v14.0 | Non-systematic Assessment |
|
| Conjunctivitis | Eye disorders | MedDRA v14.0 | Non-systematic Assessment |
|
| Eyelid oedema | Eye disorders | MedDRA v14.0 | Non-systematic Assessment |
|
| Abdominal pain | Gastrointestinal disorders | MedDRA v14.0 | Non-systematic Assessment |
|
| Constipation | Gastrointestinal disorders | MedDRA v14.0 | Non-systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | MedDRA v14.0 | Non-systematic Assessment |
|
| Acute tonsillitis | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
|
| Bronchitis | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
|
| Gastroenteritis | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
|
| Herpes zoster | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
|
| Lice infestation | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
|
| Otitis media | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
|
| Respiratory tract infection | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
|
| Rhinitis | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
|
| Scarlet fever | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
|
| Tonsillitis | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
|
| Tooth infection | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
|
| Upper respiratory tract infection | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
|
| Urinary tract infection | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
|
| Concussion | Injury, poisoning and procedural complications | MedDRA v14.0 | Non-systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA v14.0 | Non-systematic Assessment |
|
| Lordosis | Musculoskeletal and connective tissue disorders | MedDRA v14.0 | Non-systematic Assessment |
|
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA v14.0 | Non-systematic Assessment |
|
| Lipoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v14.0 | Non-systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA v14.0 | Non-systematic Assessment |
|
| Enuresis | Renal and urinary disorders | MedDRA v14.0 | Non-systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA v14.0 | Non-systematic Assessment |
|
| Eczema | Skin and subcutaneous tissue disorders | MedDRA v14.0 | Non-systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | MedDRA v14.0 | Non-systematic Assessment |
|
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
| D006728 |
| Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| Baseline (Simultaneous Processing) |
|
| Change at Month 6 (Simultaneous Processing) |
|
| Baseline (Achievement) |
|
| Change at Month 6 (Achievement) |
|
| Baseline (Nonverbal) |
|
| Change at Month 6 (Nonverbal) |
|
| Baseline (Mental Processing Composite) |
|
| Change at Month 6 (Mental Processing Composite) |
|
For K-ABC Test (Simultaneous Processing): Kruskal-Wallis ANOVA model was used to calculate p-value.
| Kruskal-Wallis |
| 0.3383 |
The statistical test was 2-sided and performed at the 5 percent significance level. |
| 95 |
| No |
| Superiority or Other |
| For K-ABC Test (Achievement): Kruskal-Wallis ANOVA model was used to calculate p-value. | Kruskal-Wallis | 0.6830 | The statistical test was 2-sided and performed at the 5 percent significance level. | 95 | No | Superiority or Other |
| For K-ABC Test (Non-Verbal): Kruskal-Wallis ANOVA model was used to calculate p-value. | Kruskal-Wallis | 0.4935 | The statistical test was 2-sided and performed at the 5 percent significance level. | 95 | No | Superiority or Other |
| For K-ABC Test (Mental Processing Composite): Kruskal-Wallis ANOVA model was used to calculate p-value. | Kruskal-Wallis | 0.3458 | The statistical test was 2-sided and performed at the 5 percent significance level. | 95 | No | Superiority or Other |
| Baseline (Alertness) |
|
| Change at 6 Month (Alertness) (n= 8, 10) |
|
| Baseline (Flexibility) |
|
| Change at 6 Month (Flexibility) (n= 8, 10) |
|
| Baseline (Go/No Go) |
|
| Change at 6 Month (Go/No Go) (n= 8, 9) |
|
| Baseline (Vigilance) |
|
| Change at 6 Month (Vigilance) (n= 7, 10) |
|
For KITAP Test (Alertness): Kruskal-Wallis ANOVA model was used to calculate p-value.
| Kruskal-Wallis |
| 0.8590 |
The statistical test was 2-sided and performed at the 5 percent significance level. |
| 95 |
| No |
| Superiority or Other |
| For KITAP Test (Flexibility): Kruskal-Wallis ANOVA model was used to calculate p-value. | Kruskal-Wallis | 1.0000 | The statistical test was 2-sided and performed at the 5 percent significance level. | 95 | No | Superiority or Other |
| For KITAP Test (Go/No Go): Kruskal-Wallis ANOVA model was used to calculate p-value. | Kruskal-Wallis | 0.1234 | The statistical test was 2-sided and performed at the 5 percent significance level. | 95 | No | Superiority or Other |
| For KITAP Test (Vigilance): Kruskal-Wallis ANOVA model was used to calculate p-value. | Kruskal-Wallis | 0.3291 | The statistical test was 2-sided and performed at the 5 percent significance level. | 95 | No | Superiority or Other |
| Baseline (Working Time) |
|
| Change at Month 6 (Working Time) |
|
| Baseline [T-scores (1)] |
|
| Change at Month 6 [T-scores (1)] |
|
| Baseline [T-scores (2)] |
|
| Change at Month 6 [T-scores (2)] |
|
| Baseline [T-scores (3)] |
|
| Change at Month 6 [T-scores (3)] |
|
| Baseline [T-scores (4)] |
|
| Change at Month 6 [T-scores (4)] |
|
| Baseline [T-scores (5)] |
|
| Change at Month 6 [T-scores (5)] |
|
| Baseline [T-scores (6)] |
|
| Change at Month 6 [T-scores (6)] |
|
| Baseline [Age-corrected T-scores (1)] |
|
| Change at Month 6 [Age-corrected T-scores (1)] |
|
| Baseline [Age-corrected T-scores (2)] |
|
| Change at Month 6 [Age-corrected T-scores (2)] |
|
| Baseline [Age-corrected T-scores (3)] |
|
| Change at Month 6 [Age-corrected T-scores (3)] |
|
| Baseline [Age-corrected T-scores (4)] |
|
| Change at Month 6 [Age-corrected T-scores (4)] |
|
| Baseline [Age-corrected T-scores (5)] |
|
| Change at Month 6 [Age-corrected T-scores (5)] |
|
| Baseline [Age-corrected T-scores (6)] |
|
| Change at Month 6 [Age-corrected T-scores (6)] |
|
| Baseline (Average time per test) |
|
| Change at Month 6 (Average time per test) |
|
| Baseline (Total time to perform 5 tests) |
|
| Change at Month 6 (Total time to perform 5 tests) |
|
| Change at Month 6 (Suprailiac SDS) |
|
Subscapular SDS: ANCOVA method was used to calculate p-value with treatment, baseline value, study duration and site as covariates. |
| ANCOVA |
| 0.3494 |
The statistical test was 2-sided and performed at the 5 percent significance level. |
| LS Mean difference |
| -0.15 |
| Standard Error of the Mean |
| 0.15 |
| 2-Sided |
| 95 |
| -0.49 |
| 0.19 |
| No |
| Superiority or Other |
| Suprailiac SDS: ANCOVA method was used to calculate p-value with treatment, baseline value, study duration and site as covariates. | ANCOVA | 0.0458 | The statistical test was 2-sided and performed at the 5 percent significance level. | LS Mean difference | -0.27 | Standard Error of the Mean | 0.12 | 2-Sided | 95 | -0.54 | -0.01 | No | Superiority or Other |